Artykuł
HIV i HPV – profilaktyka wyzwaniem każdego lekarza
19.12.2024
Terapia dwulekowa stanowi metodę optymalizacji leczenia, ale w przyszłości może być standardowym schematem postępowania antyretrowirusowego u osób zakażonych HIV.
Abstract
Recommendations for the treatment of HIV-infected patients: the role of dual therapy
The introduction of antiretroviral therapy (ARV) has completely changed the natural course of HIV infection. Previously incurable, the disease has since become a chronic disorder associated with the possibility of its course being kept well under control. The main goal of ARV treatment is to achieve virologic suppression (HIV RNA <50 copies/ml) and immune restoration (increase in the absolute number and the percentage of CD4 T cells). Currently, an individualized ARV-based treatment is recommended for all HIV-infected patients. Until recently ARV treatment has used three drugs from two different groups, when a new strategy of antiretroviral therapy emerged – dual therapy.
Piśmiennictwo
1. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv
2. World Health Organisation. https://www.who.int/
3. The Joint United Nations Programme on HIV and AIDS. https://www.unaids.org/en
4. Narodowy Instytut Zdrowia Publicznego – Państwowy Instytut Badawczy. https://www.pzh.gov.pl/
5. Krajowe Centrum ds. AIDS. https://aids.gov.pl/
6. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic HIV infection. N Engl J Med 1992;326:437-43
7. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81
8. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantyfying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-11
9. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-32
10. Günthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiretroviral therapy. J Virol 1999;73:9404-12
11. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012;60(Suppl 1):S1-18
12. Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7(5):401-10
13. Richardson ET, Grant PM, Zolopa AR. Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. Antiviral Res 2014;103:88-93
14. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016;316(2):191-210
15. Parczewski M, Jabłonowska E, Witak-Jędra M. Zasady opieki nad osobami zakażonymi HIV. Zalecenia PTN AIDS 2021. Polskie Towarzystwo Naukowe AIDS: Warszawa–Szczecin, 2021
16. Borghetti A, Lombardi F, Gagliardini R, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis 2019;19(1):59
17. Cahn P, Madero JS, Arribas JR, et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr 2020;83(3):310-18
18. Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf 2017;16(8):923-32
19. Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther 2018;12:3731-40
20. Scott LJ. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Drugs 2020;80(1):61-72
21. Rolle CP, Berhe M, Singh T, et al. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS 2021;35(12):1957-65
22. Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults. https://clinicaltrials.gov/ct2/show/NCT03945981
23. Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) 2018. https://clinicaltrials.gov/ct2/show/NCT03446573
24. Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist 2020;20:228-37
25. European AIDS Clinical Society EACS guidelines 10.0 – October 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf
26. Cabotegravir and Rilpivirine Maintains Efficancy in FLAIR 96-Week Data. https://www.contagionlive.com/view/age-sex-factors-for-heart-failure-among-hiv-patients
27. Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Supressed HIV-1-infected Adults. https://clinicaltrials.gov/ct2/show/NCT02951052
